BioProcess360

Acceleration of Bioprocess Development: IRUBIS secures Pre-Series A Funding led by BioProcess360 Partners

Biotech startup IRUBIS, developing a state-of-the-art real-time bioprocess monitoring solution, has successfully closed a pre-series A funding round. The financing round was led by BioProcess360 Partners, with participation from previous investors such as High-Tech Gründerfonds (HTGF), Verve Ventures, Ventura BioMed Investors, RoBet KG as well as new and existing business angels from the industry as Dr. Matthias Arnold and Dr. Christoph Bremus.

The funds will further enhance IRUBIS's cutting-edge solution, Monipa, tailored to empower bioprocesses with increased efficiency and precision.

Innovative Process Analytical Spectroscopy for Biomanufacturing

IRUBIS was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler, and Anja Müller with the goal of bringing life-saving biopharmaceutical drugs faster to patients. IRUBIS's innovative process analytical technology (PAT), Monipa, is based on mid-infrared spectroscopy. It serves as a user-friendly and powerful tool for the prediction of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) in upstream and downstream bioprocessing. Utilizing inline and online measurement methods aims for higher yield and better quality while bringing automatization to the production of many lifesaving drugs. This innovative approach gives Monipa great value over conventional techniques and answers many challenges in bioprocessing.

Anja Müller, CEO and Co-Founder of IRUBIS, remarked: "The pre-series A round supports IRUBIS in taking the next crucial steps, including advancing the Good Manufacturing Practices (GMP) readiness of our Monipa technology and expanding its applications in ultra-/diafiltration (UF/DF), and other downstream process steps. Additionally, we are focused on gaining more market traction and are proud to be working with over half of the key opinion leaders in the industry, solidifying our position in the biopharmaceutical sector."

Chris Major of BioProcess360 says: "I've really enjoyed building a relationship with the founders of this incredible technology. At BioProcess360 we are driven by enabling life-improving bioprocessing technologies to succeed both with capital but more importantly to provide expert guidance to our investments to ensure that these mission critical tools can be successful". He added further, "We are excited by IRUBIS's mission and look forward to providing active, hands-on support in helping them shape and implement a winning growth strategy to achieve their goals. The single use ATR crystals will be a game changer in many unit operations of both traditional mAb therapies but more so for newer modalities like gene therapy, bispecifics, antibody-drug conjugate (ADC) and nucleic acid."

Source: irubis.com